Dr. Lionel B. Ivashkiv joined Hospital for Special Surgery staff in 1992. He combines clinical care of patients with arthritis and inflammatory diseases with basic research in inflammation and gene regulation. Dr. Ivashkiv serves as head of the Rheumatoid Arthritis Registry. He is the Director of the HSS Genomics Center which was established with a $5.6 million grant from The Tow Foundation to study rheumatoid arthritis and lupus.
Attending Physician, Hospital for Special Surgery
Chief Scientific Officer, Hospital for Special Surgery
David H. Koch Chair in Arthritis and Tissue Degeneration
Professor, Medicine and Immunology, Weill Cornell Medical College
Director, HSS Genomics Center
Inflammatory bone diseases
Jack Friedman Young Investigator Prize, Weill Cornell Medical College, 1995
Young Scholar Award, Arthritis Foundation, New York Chapter, 1995
Arthritis Investigator Award, 1993
Clinical Investigator Award, 1990
Soma Weiss Award, Harvard Medical School, 1984
Blue Cross PPO
If your particular insurance plan is not listed, you may still have coverage subject to the availability of 'out-of-network' benefits. Please do not hesitate to contact our office if you have questions regarding your insurance coverage.
One of the goals of Hospital for Special Surgery (HSS) is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies if payments were received during the prior year, or if the HSS physician currently receives payment. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of August 24, 2015, Dr. Ivashkiv reported no financial interest relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, HSS’ Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
MD, Harvard Medical School, Cambridge, Massachusetts
New York University - Bellevue Hospital, New York
Harvard Medical School - Brigham and Women's Hospital
Ivashkiv, L. B. 2008. A signal switch hypothesis for cross-regulation of cytokine and TLR signaling pathways. Nature Rev. Immunology. 8:816-822. NIHMSID #72160
Hu, X., A. Chung, I. Wu, J. Foldi, J. Chen, J.-D.Ji, T. Tateya, Y. J. Kang, J. Han, M. Gessler, R. Kageyama and L. B. Ivashkiv. 2008. Selective and Reciprocal Regulation of TLR-inducible Gene Subsets by Notch and IFN-g Pathways. Immunity. 29:691-703. NIHMSID # 77245
Hu, X., S. D. Chakravarty and L. B. Ivashkiv. 2008. Regulation of IFN and TLR signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. (In Press). NIHMSID #71125
For more publications, please see the PubMed listing.
Cytokines are secreted proteins that mediate communication between cells. Cytokines trigger signal transduction and gene activation cascades that regulate cellular activation, proliferation, differentiation, and survival. A critical role for cytokines in immunity and inflammation, and in arthritis and autoimmune diseases, is now well established. New biological therapies aimed at neutralizing cytokines have been very successful and have initiated a new era of rational therapy of inflammatory and autoimmune diseases.
Our laboratory studies a major signal transduction pathway utilized by many cytokines, the Janus kinase ¡V signal transducer and activator of transcription (Jak-STAT) pathway. The laboratory is characterizing molecular mechanisms that regulate signaling by the Jak-STAT pathway. We are developing the idea that modulation or reprogramming of cytokine signaling during inflammation is an important determinant of the balance of cytokine action. We are studying the mechanisms and the impact of modulation of cytokine signaling on cell function and gene expression, and on the severity of inflammation and related tissue damage. For example, we have shown that signaling by the anti-inflammatory cytokine interleukin-10 (IL-10) is suppressed in rheumatoid arthritis (RA), such that IL-10 is no longer active. In systemic lupus erythematosus (SLE), IL-10 signaling is reprogrammed such that IL-10 acquires pro-inflammatory functions and thus contributes to inflammation instead of suppressing it. A new area of investigation in our laboratory is the analysis of cytokine regulation of tissue destruction and remodeling.
The laboratory takes an integrated bench to bedside approach and studies signal transduction defects in human disease samples, in defined in vitro systems, and in animal models of arthritis and SLE. Biochemical approaches are complemented by genetic approaches that utilize RNA interference or knockout mice, and by microarray analysis of genome-wide gene expression. The long term goals of our laboratory are to define the molecular basis of the regulation of cytokine signaling during inflammation, and to target signaling pathways as a novel approach to therapy.